A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer

BACKGROUND: 2-methoxyestradiol (2ME2) is an estradiol-17β metabolite with antiproliferative and antiangiogenic activities. ENMD-1198 is an analog of 2ME2 which was developed to decrease the metabolism and increase both the bioavailability and antitumor activities of the parent molecule. This first-i...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Zhou, Qing, Gustafson, Daniel, Nallapareddy, Sujatha, Diab, Sami, Leong, Stephen, Lewis, Karl, Gore, Lia, Messersmith, Wells A., Treston, Anthony M., Eckhardt, S. Gail, Sidor, Carolyn, Camidge, D. Ross
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4331064/
https://ncbi.nlm.nih.gov/pubmed/20084425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9383-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados